Print

Advanced Cell Technology Announces Approval to Treat Additional Stargardt’s Disease Patients With Higher RPE Dosage in Both U.S. and European Clinical Trials  
10/9/2012 9:58:10 AM

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company’s three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of second and third additional patients with Stargardt’s macular dystrophy (SMD) in the second patient cohort of its U.S. trial for the condition. Additionally, the DSMB has authorized the Company to treat all three patients in the second cohort of its European trial for SMD.
//-->